Lord, Abbett & Co
BCRX icon

Lord, Abbett & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

Lord, Abbett & Co’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-532,350
Closed -$4.77M – 536
2025
Q2 		$4.77M Buy
+532,350
New +$4.96M 0.02% 464
2022
Q2 		– Sell
-2,318,016
Closed -$37.7M – 568
2022
Q1 		$37.7M Buy
+2,318,016
New +$37.2M 0.1% 268
2015
Q4 		– Sell
-180,413
Closed -$2.06M – 883
2015
Q3 		$2.06M Sell
180,413
-367,266
-67% -$4.9M 0.01% 844
2015
Q2 		$8.18M Buy
+547,679
New +$6.23M 0.02% 677

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lord, Abbett & Co's BCRX Position: Q3 2025 in Review

Lord, Abbett & Co sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 532,350 shares — an estimated $4.77M sold.

Lord, Abbett & Co first reported a position in BCRX in Q2 2015 and held it in 4 quarters. The position peaked at $37.7M in Q1 2022. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

  • Lord, Abbett & Co reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 532,350 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $4.77M.
  • Lord, Abbett & Co first reported a position in BioCryst Pharmaceuticals in Q2 2015 and held it in 4 quarters.
  • Lord, Abbett & Co's BioCryst Pharmaceuticals position peaked at $37.7M in Q1 2022.
  • 286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Lord, Abbett & Co's 13F filing for Q3 2025, filed 13 Nov 2025.